Cover Image


Therapeutic Biological Drugs to 2020

出版商 Greystone Research Associates 商品編碼 316905
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
全球生物治療藥市場未來展望 Therapeutic Biological Drugs to 2020
出版日期: 2014年10月21日 內容資訊: 英文





  • 生物治療藥的市場空間
  • 臨床實驗與醫藥品認證
  • 競爭環境
  • 人口結構,管理護理,市場成長
  • 市場風險與機會


  • 劑型策略
    • 穩定性
    • 半衰期和治療方案
    • 免疫抗原性
  • 生物醫藥品的製劑技術
    • 移植後的緩和
    • 封裝技術
    • 緩釋性劑型
    • 連接
    • 冷凍乾燥
  • 給藥頻率
  • 治療服從性


  • 抗體
  • 酵素
  • 成長因素
  • Hematopoietics
  • 荷爾蒙
  • 免疫調節劑
  • 其他蛋白質治療水準


  • 抗病毒藥物
  • 氣喘
  • 自體免疫
  • 心臟病
  • Hematopoietics
  • 肝炎
  • 免疫療法
  • 代謝疾病
  • 多發性硬化症
  • 骨質疏鬆症
  • 腫瘤
  • 眼科疾病
  • 罕見疾病
  • 企業簡介
Product Code: TBD332F

“Therapeutic Biological Drugs to 2020: Diseases, Devices, Dosing and Forecasts” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the drug delivery sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for therapeutic proteins. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Convergence and Evolution in Key Markets

In recent years, the number of biological drugs in development and reaching the marketplace has increased significantly. The clinical application of these drugs is sometimes limited by a lack of desirable attributes for adequate absorption or distribution. So it's critical to formulate these drugs into safe, stable and efficacious delivery systems. Because these drugs face formidable enzymatic and penetration barriers when administered orally, peptide and protein drugs continue to be developed almost exclusively for parenteral administration. The growth of biological drug products is having a significant effect on the way drugs and devices are developed. Cooperation between device designers and drug developers is occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to the bioavailability targets and pharmacokinetic profiles of specific drug therapies.

What You Will Learn

  • What biological drugs are currently marketed, how are they positioned in the market, what are the device specifics, and who markets them?
  • Who are the important biological drug suppliers, their manufacturing infrastructure and locations, their capabilities?
  • What are the major factors driving biological drug demand?
  • How important are drug developer-ecosystem partner relationships and what are the key alliances in the industry?
  • What are the essential design factors, material selection issues, technologies and market development issues for biological drug products?
  • How are biological drugs aligned with various drug classes and therapeutic markets?
  • What are the significant economic, technology, and regulatory factors affecting biological drugs?

Charts, Graphs and Tables Designed to Provide Insight and Clarity

Table of Contents

Executive Summary

Biological Therapeutics Market Dynamics

  • The Biological Therapeutics Market Space
  • Clinical Trials and Drug Approvals
  • The Competitive Landscape
  • Demographics, Managed Care and Growth
  • Risks and Opportunities

Formulating Biological Drugs

  • Formulation Strategies
    • Stability
    • Half-Life & Therapeutic Protocols
    • Immunogenicity
  • Biological Formulation Technologies
    • Post-translational Modification
    • Encapsulation Technologies
    • Sustained Release Formulations
    • Conjugation
    • Lyophilization
  • Dosing Frequency
  • Treatment Compliance

Protein Drugs: Drug Analysis & Competitive Positioning

  • Antibodies
  • Enzymes
  • Growth Factors
  • Hematopoietics
  • Hormones
  • Immune Modulators
  • Other Protein Therapy Classes

Biological Drug Therapeutic Markets - Market Data and Forecasts

  • Antivirals
  • Asthma
  • Autoimmunity
  • Cardiology
  • Hematopoietics
  • Hepatitis
  • Immunotherapeutics
  • Metabolic Diseases
  • Multiple Sclerosis
  • Osteoporosis
  • Oncology
  • Ophthalmology
  • Orphan Diseases
  • <>Company Profiles
Back to Top